<a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1235408/open_sms">Send us a text</a>Decoding the message of Intercept’s Complete Response Letter Former FDA Director Brian Harvey joins the Surfers to discuss what obeticholic acid’s rejection might mean for other NASH medicines in development. Is this the end of accelerated approvals? Does it simply mean we need better drugs? Join the debate

Send us a text Decoding the message of Intercept’s Complete Response Letter Former FDA Director Brian Harvey joins the Surfers to discuss what obeticholic acid’s rejection might mean for other NASH medicines in development. Is this the end of accelerated approvals? Does it simply mean we need better drugs? Join the debate

<a href="https://www.buzzsprout.com/twilio/text_messages/1235408/open_sms" rel="noopener noreferrer">Send us a text</a>Decoding the message of Intercept’s Complete Response Letter Former FDA Director Brian Harvey joins the Surfers to discuss what obeticholic acid’s rejection might mean for other NASH medicines in development. Is this the end of accelerated approvals? Does it simply mean we need better drugs? Join the debate

What Does “No” Mean to FDA? - Ep 12

Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL

Science

Medicine

Health & Fitness

Natural Sciences

Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL

Share What Does “No” Mean to FDA? - Ep 12

Sign up to save your podcasts

What Does “No” Mean to FDA? - Ep 12

What Does “No” Mean to FDA? - Ep 12

More shows like Surfing the MASH Tsunami

Freakonomics Radio

Planet Money

Pivot

Diabetes Core Update

The School of Greatness

The Curbsiders Internal Medicine Podcast

The Daily

Up First from NPR

The Indicator from Planet Money

The Peter Attia Drive

All-In with Chamath, Jason, Sacks & Friedberg

Consider This from NPR

EASL Podcasts

Docs Who Lift

The Headlines